The recently approved BCR::ABL1 tyrosine kinase inhibitor (TKI) asciminib has demonstrated considerable activity and tolerability in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients [1]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.